Preclinical Combination Therapy of Thiarabine Plus Various Clinical Anticancer Agents

Thiarabine is undergoing clinical trials. In support of that effort combination therapy of thiarabine plus six clinical anticancer agents was evaluated using various human tumor xenograft models. The antitumor activity of thiarabine in combination appeared to be greater than additive with irinotecan...

Full description

Saved in:
Bibliographic Details
Published in:Nucleosides, nucleotides & nucleic acids nucleotides & nucleic acids, 2012-01, Vol.31 (8), p.630-646
Main Authors: Waud, William R., Gilbert, Karen S., Secrist, John A.
Format: Article
Language:English
Subjects:
4'-thio-ara-C
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Arabinonucleosides - administration & dosage
Arabinonucleosides - therapeutic use
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Cell Line, Tumor
Cisplatin - administration & dosage
clinical agents
combination therapy
Cyclophosphamide - administration & dosage
Female
HT29 Cells
human tumor xenografts
Humans
Male
Mice
Mice, Nude
Mice, SCID
Neoplasms - drug therapy
Neoplasms - pathology
Paclitaxel - administration & dosage
Thiarabine
Tumor Burden - drug effects
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thiarabine is undergoing clinical trials. In support of that effort combination therapy of thiarabine plus six clinical anticancer agents was evaluated using various human tumor xenograft models. The antitumor activity of thiarabine in combination appeared to be greater than additive with irinotecan (DLD-1 colon), paclitaxel (PC-3 prostate), cisplatin (PC-3 prostate), or cyclophosphamide (RL lymphoma), additive with irinotecan (NCI-H460 NSCLC), cisplatin (NCI-H460 NSCLC) or methotrexate (CCRF-CEM leukemia), and less than additive with irinotecan (HT29 colon), paclitaxel (NCI-H460 NSCLC) or cisplatin (NCI-H23 NSCLC). Combining thiarabine with irinotecan, paclitaxel, cisplatin, or cyclophosphamide should receive consideration in the clinical treatment of cancer.
ISSN:1525-7770
1532-2335
DOI:10.1080/15257770.2012.712181